

Date: May 12, 2025

Ref. No.: KDL/SE/014/2025-26

To, BSE Limited Corporate Relationship Department 25th Floor, Phiroze Jeejeebhoy Towers Dalal Street, Mumbai- 400001 Scrip Code: 543328	To, National Stock Exchange of India Limited Exchange Plaza, Plot No. C-1, Block G, Bandra Kurla Complex, Bandra (East) Mumbai – 400051 NSE Symbol: KRSNAA
--	--

Dear Sir/Madam,

Sub: Press Release – Audited Financial Results (Standalone and Consolidated) for the quarter and Year ended March 31, 2025.

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith the Press Release on the audited (Standalone and Consolidated) Financial Results for the quarter and year ended March 31, 2025.

For Krsnaa Diagnostics Limited



Sujoy Sudipta Bose
Company Secretary & Compliance Officer
Encl: as above

Krsnaa Diagnostics Ltd.

S.No. 243/A, Hissa No. 6, CTS No. 4519, 4519/1, Near Chinchwad Station,
Chinchwad, Taluka - Haveli, Pune, MH - 411019 (India)
020 27402400 | info@krsnaa.in



Company Delivers Industry-Leading 37% Surge in Profit After Tax, Driven by Robust 16% Revenue Growth

Pune, May 12, 2025: Krsnaa Diagnostics Ltd. ([BSE: 543328](#) | [NSE: KRSNAA](#)) is one of India's fastest-growing diagnostic service providers, both in radiology and pathology. The Company today announced the results for the quarter & full year ending March 31st, 2025.

Financial Performance FY2025

Revenue ₹ 717 cr 16% YoY ↑
EBIDTA ₹ 196 cr 34% YoY ↑
PAT ₹ 78 cr 37% YoY ↑
EPS ₹ 23.56 36% YoY ↑
Dividend recommended 55%

Financial Overview Q4 FY2025:

(Rs. Million)	Q4FY25	Q4FY24	Y-o-Y Growth	Q3FY25	Q-o-Q Growth	FY25	FY24	Y-o-Y Growth
Revenue from Operations	1,861	1,663	12%	1,745	7%	7,172	6,196	16%
Other Income	44	43		92		255	168	
Total Income	1,905	1,706		1,837		7,427	6,364	
EBITDA ¹	542	441	23%	466	16%	1,958	1,466	34%
Margin %	29%	27%		27%		27%	24%	
EBIT ¹	354	299	18%	316	12%	1,273	865	47%
Margin %	16%	18%		17%		17%	14%	
Profit After Tax	207	187	11%	194	7%	776	568	37%
Margin %	11%	11%		11%		11%	9%	
Reported `Diluted EPS	6.30	5.70	11%	5.88	7%	23.56	17.31	36%

Notes:

1. EBITDA excludes CSR and ESOP and EBIT includes Other Income

Commenting on the results, **Mr. Yash Mutha, Managing Director**, said:

“We are pleased to report the strongest Profit After Tax (PAT) growth since our listing, with PAT reaching ₹776 million in FY25 — a 37% year-on-year increase. This exceptional performance was driven by higher volumes and improved operational efficiency.

Krsnaa is executing several strategic initiatives to diversify its revenue streams beyond its current B2G-focused model. As part of our transition to an asset-light business model, we have entered into strategic partnerships with Medikabazaar and United Imaging to procure over 30 imaging machines on a deferred payment basis. We are also expanding into high-end PET-CT (oncology care) services through investments in Apulki Healthcare. Additionally, we are leveraging the Krsnaa brand at PPP centres to penetrate the B2C market. These initiatives will drive sustained growth, improve realizations, and reduce capex intensity, thereby enhancing the return ratios of the business.

Krsnaa has delivered impressive growth over the last five years and is well-positioned for continued growth. Our unique business model targets the underserved markets in tier 2–3 cities, offering significant volume growth potential, especially as more states adopt the PPP model for free diagnostic schemes. Our nationwide offerings in pathology and radiology mitigate concentration risk and create economies of scale.

In FY25, Krsnaa achieved a remarkable 16% year-on-year revenue growth, reaching Rs. 7,172 million. Increased awareness of our high-quality services, combined with competitive pricing, has led to a significant rise in patient volumes and test counts. On the financial front, EBITDA surged 34% YoY to Rs. 1,958 million, with improved margins of 27%. Net profit rose 37% YoY to Rs. 776 million, with net margins at 11%, reflecting our ongoing commitment to operational efficiency through strategic initiatives. We remain confident in sustaining this positive momentum in the quarters ahead.

Looking forward, our senior management is fully committed to executing our growth strategies. We are actively expanding our participation in tenders and strengthening our pipeline to ensure sustained growth. With a clear vision and disciplined execution, we are poised to further solidify our market leadership.”

Commenting on the Business, **Ms. Pallavi Bhatevara, Executive Director**, said:

“At Krsnaa Diagnostics Limited, we leverage the Public-Private Partnership (PPP) model to provide free diagnostic services across India, with a strong pan-India presence. We have established ourselves as a key player in delivering high-quality and affordable diagnostic services, which are essential for disease diagnosis, management, and prevention. These services form a fundamental pillar of the healthcare industry.

The Indian diagnostics industry, historically fragmented with a network of unorganized players, has experienced steady growth. The market registered an 8% CAGR over the past five years, reaching approximately US\$ 12 billion in FY24. Within this context, the organized segment, consisting of national and regional diagnostic chains, has outpaced the broader market, achieving a 12% CAGR. This makes diagnostics one of the fastest-growing segments in the Indian healthcare sector. However, despite this steady expansion, diagnostics penetration in India remains among the lowest globally, even when compared to other developing nations.

Krsnaa's Free Diagnostics Services has already made significant strides. To date, 12 states and Union Territories (UTs) have adopted free pathology services through the PPP model, and 19 states/UTs have adopted free radiology services, highlighting substantial untapped potential. State-level allocations for diagnostics have grown at an 18% CAGR, significantly outpacing the broader industry growth rate.

Krsnaa has effectively capitalized on these opportunities, securing pathology tenders in 8 out of 12 states and winning radiology tenders in 12 out of 19 states, resulting in an impressive 75% win-to-bid ratio. This strong performance positions Krsnaa Diagnostics as the leading PPP player, offering a fully integrated service portfolio across radiology, pathology, and teleradiology.”

About Krsnaa Diagnostics:

Krsnaa Diagnostics Ltd. is India's fastest growing differentiated diagnostic services provider, both in Radiology and Pathology. The company started its journey in 2011 with 2 radiology centre and today it is in 15 states and 3 Union Territories with 4,000+ centres across the country. Our mission to be easily accessible and affordable to anyone who seeks best quality diagnosis, and our commitment towards the same is what defines and differentiates us. We deliver clinical excellence through collaborative teleradiology services to enable robust evidence-based treatment for our patients in any corner of the country. With the most advanced technology in place, equipped with an advanced cloud based PACS workflow capable of rapid deployment and easy integration into flexible operational needs, accurate reports are delivered from well-qualified Radiologists and Pathologists from across the globe. We offer exceptional service with prompt turnaround of diagnostic reports, easy access to consultation with our team of diagnostic specialists, and the ability to handle diagnostic report needs. We provide world class healthcare diagnostics services at affordable rates with the approach of "Let's Do Good...".

For further information, please contact

Vivek Jain

Head - Investor Relation

Krsnaa Diagnostics Ltd.

+91 74107 00645

head.investor@krsnaa.in

Safe Harbour

This press release may include statements of future expectations and other forward-looking statements based on management's current expectations and beliefs concerning future developments and their potential effects upon Krsnaa Diagnostics Ltd and its subsidiaries/associates ("Krsnaa Diagnostics"). These forward-looking statements involve known or unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others: general economic and business conditions in India and overseas, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, change in laws and regulations that apply to the related industries, increasing competition in and the conditions of the related industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither Krsnaa Diagnostics, nor our directors, or any of our subsidiaries/associates assume any obligation to update any forward-looking statement contained in this release.